There are more than 7,000 orphan diseases in existence today, and yet only about 5% of them have treatment available. We recognize the tremendous unmet medical needs and a real opportunity to make a meaningful difference in the lives of these patients and families. As such, LifeMax dedicates itself to the development of first-in-class or best-in-class therapeutics for orphan diseases. Through licensing and collaboration, we have built a robust and science-driven portfolio that addresses critical unmet medical needs for the treatment of orphan diseases. We continue to expand the pipeline with a focus on modalities that target the underlying genetic cause. With its robust pipeline and seasoned management team, LifeMax is well positioned to grow into a leader in the development and commercialization of novel orphan drugs.
LifeMax is a privately held, clinical stage biotech company focused on developing first-in-class or best-in-class therapeutics for orphan diseases that have few or no options. Our lead program, LM-030, is ready to enter into a pivotal trial for the treatment of Netherton syndrome.
LifeMax was established by four founders, led by Dr. Larry Hsu, a well-known entrepreneur and industry veteran, with a goal to build a company that would become a leader in the development and commercialization of much needed therapeutics to address critical unmet medical needs. LifeMax distinguishes itself from other biotech companies with an experienced management team that has a proven track record of having successfully built a fully integrated multi-billion dollar NASDAQ-listed US pharmaceutical company.
means that our portfolio selection is focused on unmet market needs instead of platform technologies. We strive to bring first-in-class or best-in-class therapeutics that will offer meaningful and significant clinical benefits to patients who suffer from orphan diseases with few or no treatment options.
means that our portfolio selection is driven by scientific understanding of the disease pathology and therapeutic targets. Targeting the underlying genetic abnormality represents a mechanistically rational approach that would more likely reduce the development risk of our portfolio.
means that we are leveraging our in-depth yet broad expertise in drug development to speed up the development of our portfolio towards global regulatory approval and commercialization.